Chimeric receives $1.62M advance on FY26 R&D tax incentive
Open PDF
| Stock | Chimeric Therapeutics Ltd (CHM.ASX) |
|---|---|
| Release Time | 29 Jul 2026, 2:10 p.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Chimeric Therapeutics Receives $1.62M Advance on FY26 R&D Tax Incentive
Key Points
- Chimeric Therapeutics secures $1.62M advance from Endpoints Capital
- Funds will support Phase 1/2 clinical trial activities
- Repayment tied to FY26 Research and Development Tax Incentive
Full Summary
Chimeric Therapeutics Ltd., an Australian cell therapy company, has secured a $1.62 million advance from Endpoints Capital under a funding facility secured against its anticipated FY26 Research and Development Tax Incentive (RDTI). This funding will support ongoing Phase 1/2 clinical trial activities and general working capital. The funding agreement provides Chimeric with early access to a portion of the anticipated FY26 RDTI, with interest charged at a commercial rate. Repayment is due by December 31, 2026, and can be repaid earlier subject to the terms of the facility.
Guidance
None
Outlook
None
Sign in to get more information about the company, including guidance changes and other insights.
Sign In